Filing search / Legend Biotech Corporation / "Safety"

6-K

LEGN Legend Biotech Corporation

15 Oct 24

Current report (foreign)

7:30am

requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions

6-K

EX-99.1

LEGN Legend Biotech Corporation

27 Sep 24

Current report (foreign)

4:35pm

percent CI, 32.20-NE) with patients treated with standard therapies (HR, 0.38, 95 percent CI, 0.24-0.61; p<0.0001).1 The safety profile of cilta-cel … versus standard therapies was consistent with previous results. In the safety analysis [cilta-cel, n=208, standard therapies, n=208], 97 percent

6-K

LEGN Legend Biotech Corporation

9 Aug 24

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

7:01am

or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays … safety profile. On February 28, 2022, cilta-cel was approved by the U.S. Food and Drug Administration (the “FDA”) under the trademark CARVYKTI

6-K

EX-99.4

LEGN Legend Biotech Corporation

9 Aug 24

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

7:01am

. #Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses under investigation have not been

6-K

EX-99.1

LEGN Legend Biotech Corporation

9 Aug 24

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

7:01am

analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety

6-K

ldnex3q

26 Jul 24

Current report (foreign)

7:00am

6-K

EX-99.1

sr9uomu cpz

26 Jul 24

Current report (foreign)

7:00am

6-K

h5h1d5eybpsa

17 Jul 24

Current report (foreign)

7:30am

6-K

EX-99.1

det5f

2 Jul 24

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

8:00am

6-K

aye9pftc5qdp

2 Jul 24

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

8:00am

6-K

EX-99.1

9tgao3a y7zr5x

3 Jun 24

Current report (foreign)

4:05pm

6-K

EX-99.1

0jip44ft2pro1dcl78nt

23 May 24

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

5:00pm

6-K

EX-99.1

3zs 69w9q4d5in1

13 May 24

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

7:01am

6-K

ogv3s5pgbxr9l6mlgs1t

13 May 24

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

7:01am

6-K

EX-99.1

2pyo8hylue24wekcz909

22 Apr 24

Current report (foreign)

1:06pm

6-K

3g0bx1oi 5zltwtg77eu

16 Apr 24

Current report (foreign)

7:29am

6-K

EX-99.1

3jnarb4nnc4u i5b3

8 Apr 24

Current report (foreign)

7:03am

F-3ASR

ooed90imqw

19 Mar 24

Automatic shelf registration (foreign)

7:57am